SCHEMBL26315520

SCHEMBL26315520

CC(C)(C)c1ccc2cnc(CC(C)(C)c3ccc4ncccc4c3)cc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.39
ATM Q13315 2/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
POLB P06746 1/20 0.38
MET P08581 4/20 0.36
GNRHR P30968 1/20 0.35
METAP2 P50579 1/20 0.35
TRPV1 Q8NER1 3/20 0.35
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22617566 0.84 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL20932780 0.81 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL21497381 0.80 PRKCZ (0.35) MAPTTRPV1CYP3A4CYP2D6SLC6A2
SCHEMBL264293 0.80 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL19750751 0.77 MAPT (0.38) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL21497380 0.77 GNRHR (0.41) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL22078503 0.76 PDE10A (0.35) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL19424168 0.75 PDE10A (0.45) METAP2TRPV1SLC6A4PDE10A
SCHEMBL10285521 0.74 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MAPTATMHTT
SCHEMBL24904290 0.74 MAPT (0.38) ALDH1A1SMN1; SMN2MAPTATMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278993-A1 NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278993-A1 NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF PDCD1, CD274, PDCD1LG2 ALDH1A1 216/4885SMN1; SMN2 3869/4885MAPT 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.